Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CUGBP Elav-like family member 3 (CELF3) is an RNA-binding protein that regulates pre-mRNA alternative splicing, particularly by mediating tissue-specific and developmentally regulated inclusion or exclusion of exons during mRNA maturation. It binds to specific sequence motifs within pre-mRNA and can influence the splicing of key targets such as TNNT2 (encoding cardiac troponin T) and MAPT (encoding Tau protein), thereby impacting post-transcriptional gene expression. CELF3 is associated with certain neurodevelopmental disorders, including specific language impairment and reading disorder, but it is not currently classified as a direct therapeutic target or known to interact with approved drugs
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CUGBP Elav-like family member 3 (CELF3).